Vedolizumab (Entyvio)

Description

Vedolizumab is a humanized monoclonal antibody that selectively targets gut-associated lymphoid tissue and is primarily approved for inflammatory bowel diseases including ulcerative colitis and Crohn's disease. In the context of colorectal cancer, vedolizumab is being explored as a treatment for immune checkpoint inhibitor-induced colitis, a serious adverse effect that can occur when cancer patients receive immunotherapy treatments. This gut-selective immunosuppressive agent offers a targeted approach to managing severe gastrointestinal inflammation without broadly suppressing the systemic immune system.

Mechanism of Action

Vedolizumab specifically binds to the ?4 7 integrin expressed on gut-homing T-helper lymphocytes and blocks their interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on gut endothelial cells. This selective blockade prevents inflammatory lymphocytes from migrating into gastrointestinal tissues, thereby reducing intestinal inflammation while preserving systemic immune function.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials